{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:43:00Z","timestamp":1770057780355,"version":"3.49.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,15]]},"DOI":"10.2146\/ajhp160205","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T10:08:18Z","timestamp":1467799698000},"page":"1058-1075","source":"Crossref","is-referenced-by-count":65,"title":["National trends in prescription drug expenditures and projections for 2016"],"prefix":"10.1093","volume":"73","author":[{"given":"Glen T.","family":"Schumock","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, University of New England, Portland, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Edwards Hines Jr. VA Hospital, Hines, IL"},{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Wiest","sequence":"additional","affiliation":[{"name":"UC Health, Cincinnati, OH"},{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Stubbings","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Matusiak","sequence":"additional","affiliation":[{"name":"IMS Health, Plymouth Meeting, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hunkler","sequence":"additional","affiliation":[{"name":"IMS Health, Plymouth Meeting, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee C.","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Center for Clinical Knowledge Management, UW Health, Madison, WI"},{"name":"School of Pharmacy, University of Wisconsin, Madison, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041604490573900_b1-0731058","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1377\/hlthaff.2015.1194","article-title":"National health spending in 2014: faster growth driven by coverage expansion and prescription drug spending","volume":"35","author":"Martin","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"2019041604490573900_b2-0731058","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1377\/hlthaff.2015.0600","article-title":"National health expenditure projections, 2014\u201324: spending growth faster than recent trends","volume":"34","author":"Keehan","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"2019041604490573900_b3-0731058","unstructured":"Freundlich\n              N\n            \n          . Keep the focus on rising drug prices, not smirking Shkreli (February08, 2016). http:\/\/reforminghealth.org\/2016\/02\/08\/keep-the-focus-on-rising-drug-prices-not-smirking-shkreli\/ (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b4-0731058","unstructured":"Thomas\n              Z\n            \n            \n              Swift\n              T\n            \n          . Who is Martin Shkreli\u2014\u2019the most hated man in America\u2019? (September23, 2015). www.bbc.com\/news\/world-us-canada-34331761 (accessed 2016 Mar 3)."},{"key":"2019041604490573900_b5-0731058","unstructured":"Winslow\n              R\n            \n          . Cost of skin drugs rising rapidly, study shows (November26, 2015). www.wsj.com\/articles\/prescription-skin-drugs-explode-in-costs-study-shows-1448467254 (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b6-0731058","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jval.2015.10.008","article-title":"Thirty years of media coverage on high drug prices in the United States\u2014a never-ending story or a time for change?","volume":"19","author":"Leopold","year":"2016","journal-title":"Value Health"},{"key":"2019041604490573900_b7-0731058","unstructured":"Johnson\n              C\n            \n            \n              Dennis\n              B\n            \n          . How an $84,000 drug got its price: \u2018let\u2019s hold our position \u2026 whatever the headlines\u2019. (December15, 2015). www.washingtonpost.com\/news\/wonk\/wp\/2015\/12\/01\/how-an-84000-drug-got-its-price-lets-hold-our-position-whatever-the-headlines\/ (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b8-0731058","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.mayocp.2015.06.001","article-title":"In support of a patient-driven initiative and petition to lower the high price of cancer drugs","volume":"90","author":"Tefferi","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2019041604490573900_b9-0731058","unstructured":"Rocco\n              P\n            \n            \n              Gellad\n              W\n            \n            \n              Donohue\n              J\n            \n          . How much does Congress care about drug prices? Less than it should (January13, 2016). http:\/\/healthaffairs.org\/blog\/2016\/01\/13\/how-much-does-congress-care-about-drug-pricesless-than-it-should\/ (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b10-0731058","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2146\/ajhp130767","article-title":"National trends in prescription drug expenditures and projections for 2014","volume":"71","author":"Schumock","year":"2014","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041604490573900_b11-0731058","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2146\/ajhp140849","article-title":"National trends in prescription drug expenditures and projections for 2015","volume":"72","author":"Schumock","year":"2015","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041604490573900_b12-0731058","volume-title":"Plymouth Meeting","author":"National Sales Perspectives [proprietary database]","year":"2016"},{"key":"2019041604490573900_b13-0731058","unstructured":"IMS Health. Uniform System of Classification (March2008). www.imshealth.com\/files\/web\/IMSH%20Institute\/USC_Classiification_Process_2011.p (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b14-0731058","unstructured":"Biogen. FDA accepts biologics license application for Zinbryta (daclizumab high-yield process) for treatment of MS (April29, 2015). http:\/\/media.biogen.com\/press-release\/corporate\/fda-accepts-biologics-license-application-zinbryta-daclizumab-high-yield-pro (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b15-0731058","unstructured":"Gilead Sciences. Gilead submits new drug application to U.S. Food and Drug Administration for single tablet regimen for HIV containing rilpivirine, emtricitabine and tenofovir alafenamide (R\/F\/TAF) (July15, 2015). www.gilead.com\/news\/press-releases\/2015\/7\/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-single-tablet-regimen-for-hiv-containing-rilpivirine-emtricitabine-and-tenofovir-alafenamide-rftaf (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b16-0731058","unstructured":"Gilead Sciences. Gilead submits new drug application to U.S. Food and Drug Administration for fixed-dose combination of emtricitabine\/tenofovir alafenamide for HIV treatment (April07, 2015). www.gilead.com\/news\/press-releases\/2015\/4\/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixeddose-combination-of-emtricitabine-tenofovir-alafenamide-for-hiv-treatment (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b17-0731058","unstructured":"PR Newswire. FDA accepts Bayer\u2019s biologics license application for investigational treatment option in hemophilia A (March04, 2015). www.prnewswire.com\/news-releases\/fda-accepts-bayers-biologics-license-application-for-investigational-treatment-option-in-hemophilia-a-300045306.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b18-0731058","unstructured":"PR Newswire. Jazz Pharmaceuticals announces U.S. FDA acceptance for filing with priority review of NDA for defibrotide for hepatic veno-occlusive disease (September30, 2105). www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-announces-us-fda-acceptance-for-filing-with-priority-review-of-nda-for-defibrotide-for-hepatic-veno-occlusive-disease-300151412.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b19-0731058","unstructured":"Business Wire. Xadago (safinamide) new drug application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) (March02, 2015). www.businesswire.com\/news\/home\/20150302006405\/en\/Xadago%C2%AE-safinamide-Drug-Application-NDA-Accepted-Filing (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b20-0731058","unstructured":"Gilead Sciences. Gilead announces U.S. FDA priority review designation for sofosbuvir\/velpatasvir for treatment of all genotypes of chronic hepatitis C infection (January04, 2016). www.gilead.com\/news\/press-releases\/2016\/1\/gilead-announces-us-fda-priority-review-designation-for-sofosbuvirvelpatas-vir-for-treatment-of-all-genotypes-of-chronic-hepatitis-c-infection (accessed 2016 Feb 2)."},{"key":"2019041604490573900_b21-0731058","unstructured":"Teva Pharmaceutical Industries Ltd. Teva announces FDA acceptance of the biologics license application for reslizumab (June15, 2015). www.tevapharm.com\/news\/teva_announces_fda_acceptance_of_the_biologics_license_application_for_reslizumab_06_15.aspx (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b22-0731058","unstructured":"Intercept. FDA extends PDUFA date for obeticholic acid for the treatment of PBC (December17, 2015). https:\/\/globenewswire.com\/news-release\/2015\/12\/17\/796641\/0\/en\/FDA-Extends-PDUFA-Date-for-Obeticholic-Acid-for-the-Treatment-of-PBC.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b23-0731058","unstructured":"Sanofi. Sanofi new drug application for lixisenatide accepted for review by FDA (September29, 2015). www.news.sanofi.us\/2015-09-29-Sanofi-New-Drug-Application-for-Lixisenatide-Accepted-for-Review-by-FDA (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b24-0731058","unstructured":"Business Wire. Acadia Pharmaceuticals announces FDA priority review of Nuplazid (pimavanserin) new drug application for Parkinson\u2019s disease psychosis (November02, 2015). www.businesswire.com\/news\/home\/20151102005516\/en\/ACADIA-Pharmaceuticals-Announces-FDA-Priority-Review-NUPLAZID%E2%84%A2 (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b25-0731058","unstructured":"Business Wire. Teva announces FDA acceptance of NDA for SD-809 for treatment in Huntington disease (August12, 2015). www.businesswire.com\/news\/home\/20150812005421\/en\/Teva-Announces-FDA-Acceptance-NDA-SD-809-Treatment (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b26-0731058","unstructured":"Roche. FDA grants priority review for venetoclax new drug application (January12, 2016). www.roche.com\/investors\/updates\/inv-update-2016-01-12.htm (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b27-0731058","unstructured":"PR Newswire. FDA accepts Amgen\u2019s new drug application for novel intravenous calcimimetic Etelcalcetide (November06, 2015). www.prnewswire.com\/news-releases\/fda-accepts-amgens-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-300174208.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b28-0731058","unstructured":"PR Newswire. Valeant announces FDA acceptance of BLA submission for brodalumab in moderate-to-severe plaque psoriasis (January25, 2015). www.prnewswire.com\/news-releases\/valeant-announces-fda-acceptance-of-bla-submission-for-brodalumab-in-moderate-to-severe-plaque-psoriasis-300208845.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b29-0731058","unstructured":"PR Newswire. Regeneron and Sanofi announce sarilumab biologics license application accepted for review by US FDA (January08, 2016). www.prnewswire.com\/news-releases\/regeneron-and-sanofi-announce-sarilumab-biologics-license-application-accepted-for-review-by-us-fda-300201389.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b30-0731058","unstructured":"Taylor\n              P\n            \n          . Roche prepares to file atezolizumab for bladder cancer (January08, 2016). www.pmlive.com\/pharma_news\/roche_prepares_to_file_atezolizumab_for_bladder_cancer_901572 (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b31-0731058","unstructured":"Eli Lilly and Company. Lilly and Incyte announce submission of new drug application to FDA for oral once-daily baricitinib for treatment of moderate-to-severe rheumatoid arthritis (January19, 2016). https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=950678 (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b32-0731058","unstructured":"Food and Drug Administration. FDA news release: FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 (January28, 2016). www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm483828.htm (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b33-0731058","unstructured":"Food and Drug Administration. FDA news release: FDA approves first coagulation factor\u2013albumin fusion protein to treat patients with hemophilia B (March04, 2016). www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm489266.htm (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b34-0731058","unstructured":"Taylor\n              S\n            \n          . Digest: generic and biosimilar pipeline September 2015 to December 2018 (2015). https:\/\/www.futurescripts.com\/FutureScripts\/pdfs\/for_members\/Q3_2015_Generic_Pipeline_Report.pdf (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b35-0731058","unstructured":"Express Scripts. Issues document: patent expirations (2013\u20132017) (May06, 2013). www.centerlighthealthcare.org\/images\/uploads\/Brand_Name_Drugs_with_Patent_Expirations_2013_-_2017.pdf (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b36-0731058","unstructured":"Stone\n              K\n            \n          . Which popular drugs are going off patent in 2013\u20132016? (December16, 2014). http:\/\/pharma.about.com\/od\/BigPharma\/a\/Which-Popular-Drugs-Are-Going-Off-Patent-In-2013-2016.htm (accessed 2016 Feb 29)."},{"key":"2019041604490573900_b37-0731058","unstructured":"EP Vantage. Breakthrough designation quickens FDA approval pace in 2014 (January05, 2015). http:\/\/epvantage.com\/Universal\/View.aspx?type=Story&id=550480&isEPVantage=yes (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b38-0731058","unstructured":"Eli Lilly and Company. Lilly receives FDA breakthrough therapy designation for abemaciclib\u2014a CDK 4 and 6 inhibitor\u2014in advanced breast cancer (October08, 2015). www.prnewswire.com\/news-releases\/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib\u2013a-cdk-4-and-6-inhibitor\u2013in-advanced-breast-cancer-300156371.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b39-0731058","unstructured":"AstraZeneca. Durvalumab granted breakthrough therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer (February17, 2016). www.astrazeneca.com\/media-centre\/press-releases\/2016\/Durvalumab-granted-Breakthrough-Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html (accessed 2016 Feb 22)."},{"key":"2019041604490573900_b40-0731058","volume-title":"Redbook Online [online database]"},{"key":"2019041604490573900_b41-0731058","unstructured":"Food and Drug Administration. Unapproved drugs initiative (December15, 2014). www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/EnforcementActivitiesbyFDA\/SelectedEnforcementActionsonUnapprovedDrugs\/ucm118990.htm (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b42-0731058","volume-title":"Global medicines use in 2020: outlook and implications","author":"Aitken","year":"2015"},{"key":"2019041604490573900_b43-0731058","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp1515068","article-title":"Pharmaceutical policy reform\u2014balancing affordability with incentives for innovation","volume":"374","author":"Conti","year":"2016","journal-title":"N Engl J Med"},{"key":"2019041604490573900_b44-0731058","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1377\/hlthaff.2014.0560","article-title":"National health expenditure projections, 2013\u201323: faster growth expected with expanded coverage and improving economy","volume":"33","author":"Sisko","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"2019041604490573900_b45-0731058","unstructured":"The Express Scripts Labs. Express Scripts 2015 drug trend report (March2016). http:\/\/lab.express-scripts.com\/lab\/drug-trend-report (accessed 2016 Apr 4)."},{"key":"2019041604490573900_b46-0731058","unstructured":"Food and Drug Administration. Novel new drugs: 2014 summary (January2015). www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DrugInnovation\/UCM430299.pdf (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b47-0731058","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"key":"2019041604490573900_b48-0731058","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C (2016). www.hcvguidelines.org (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b49-0731058","unstructured":"Centers for Medicare and Medicaid Services. Medicaid drug rebate program notice: assuring Medicaid beneficiaries\u2019 access to hepatitis C (HCV) drugs (November05, 2015). www.medicaid.gov\/Medicaid-CHIP-Program-Information\/By-Topics\/Benefits\/Prescription-Drugs\/Downloads\/Rx-Releases\/State-Releases\/state-rel-172.pdf (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b50-0731058","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2015.13414","article-title":"Predicting the overuse of PCSK-9 inhibitors","volume":"314","author":"Rodriguez-Gutierrez","year":"2015","journal-title":"JAMA"},{"key":"2019041604490573900_b51-0731058","unstructured":"EMD Serono. EMD Serono specialty digest, 11th edition. www.specialtydigest.emdserono.com\/Digest.aspx (accessed 2016 Feb 1)."},{"key":"2019041604490573900_b52-0731058","article-title":"Developing a specialty pharmacy strategy: building a successful business model","author":"Colgan"},{"key":"2019041604490573900_b53-0731058","unstructured":"Ignjatovic\n              T\n            \n          . Biosimilars still to make an impact in the UK (July10, 2013). www.datamonitorhealthcare.com\/biosimilars-still-to-make-an-impact-in-the-uk\/ (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b54-0731058","unstructured":"Pollack\n              A\n            \n          . Drug goes from $13.50 a tablet to $750 overnight (September20, 2015). www.nytimes.com\/2015\/09\/21\/business\/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?_r=0 (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b55-0731058","unstructured":"American Society of Health-System Pharmacists. ASHP statement for the record: \u201cdevelopments in the prescription drug market\u201d (February04, 2016). www.ashp.org\/menu\/Advocacy\/FederalIssues\/OtherIssues\/ASHP-Statement-for-the-Record-Developments-in-the-Prescription-Drug-Market.html (accessed 2016 Mar 2)."},{"key":"2019041604490573900_b56-0731058","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2015.13498","article-title":"Options to promote competitive generics markets in the United States","volume":"314","author":"Wiske","year":"2015","journal-title":"JAMA"},{"key":"2019041604490573900_b57-0731058","unstructured":"Health Resources and Services Administration. 340B Drug Pricing Program omnibus guidance (August28, 2015). www.federalregister.gov\/articles\/2015\/08\/28\/2015-21246\/340b-drug-pricing-program-omnibus-guidance (accessed 2016 Mar 30)."},{"key":"2019041604490573900_b58-0731058","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2146\/ajhp140850","article-title":"Accuracy of annual prescription drug expenditure forecasts in AJHP","volume":"72","author":"Hartke","year":"2015","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041604490573900_b59-0731058","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ajhp\/62.2.149","article-title":"Projecting future drug expenditures\u20142005","volume":"62","author":"Hoffman","year":"2005","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041604490573900_b60-0731058","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2146\/ajhp080021","article-title":"ASHP guidelines on medication cost management strategies for hospitals and health systems","volume":"65","author":"American Society of Health-System Pharmacists","year":"2008","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041604490573900_b61-0731058","unstructured":"Amgen. FDA approves Imlygic (talimogene laherparepvec) as first oncolytic viral therapy in the US (October27, 2015). www.amgen.com\/media\/news-releases\/2015\/10\/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us\/ (accessed 2016 Feb 22)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/14\/1058\/28450212\/ajhp1058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T08:53:37Z","timestamp":1555404817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/14\/1058\/5101626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":61,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,7,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160205","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7,15]]},"published":{"date-parts":[[2016,7,15]]}}}